The presentations were made by Noah Petro and Barbara Cohen, NASA’s Artemis III and IV mission science leads from the Goddard ...

Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc Brian Deschuytner; Chief Financial Officer, Chief Operating Officer, Senior Vice President; Mersana Therapeutics ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Good morning, and welcome to Mersana Therapeutics First Quarter 2025 ...

At the NewFronts, executives said that generative AI tools are “are going to help mark a new era of creativity” that ...

GAAP operating loss in the first quarter of 2025 was $17.8 million compared to operating loss of $7.1 million in the first quarter of 2024. Non-GAAP operating loss was $15.3 million in the first ...

Brain tumors strike over 25,000 Americans annually with often subtle warning signs. Learn crucial facts about detection, ...

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have ...

At New Zealand’s latest mutual evaluation, the Financial Action Task Force (FATF) reported on several strengths in the New ...

The median age at symptom onset in the cohort was 55 years, ranging from 16 to 81 years. Data from patients’ initial ...

Environmental policy & sustainability management graduates understand that we must do better to address our world's problems.

Berlin as a meeting destination will be showcasing itself and launching new Impact Programme at IMEX Frankfurt from 20 to 22 ...

Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics ...